BindingDB logo
myBDB logout

300 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28274635 381 Identification of novel TACE inhibitors compatible with topical application.EBI Nestl� Skin Health R & D
27966948 86 Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.EBI Pharmaceutical Company Limited
28337319 28 Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.EBI Universit£ di Pisa
27914947 11 Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).EBI University of Florence
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Co., Ltd
27452283 241 Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.EBI Jadavpur University
26871660 68 Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI San Raffaele Scientific Institute
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26263024 47 N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI Universit£ di Pisa
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Co., Ltd
25265401 38 Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI Universidad CEU San Pablo
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1┐ binding site.EBI Takeda Pharmaceutical Co., Ltd
24735644 19 Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-▀ hydrolysis.EBI University of Lille
23376997 53 Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.EBI Universit£ di Pisa
23375794 220 Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.EBI Nanjing University of Chinese Medicine
23353736 41 Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).EBI Second Military Medical University
23287054 46 Sulphonamides: Deserving class as MMP inhibitors?EBI Indian Institute of Technology (BHU)
23458498 24 Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI Universit£ del Piemonte Orientale"Amedeo Avogadro"
17275314 701 Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI Pomona College
23134659 74 Design and synthesis of procollagen C-proteinase inhibitors.EBI FibroGen Inc
22891645 83 Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).EBI GlaxoSmithKline
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
21413800 56 A one-pot synthesis and biological activity of ageladine A and analogues.EBI Macquarie University
22737278 44 Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI TBA
22658537 76 Natural products as a gold mine for selective matrix metalloproteinases inhibitors.EBI East China University of Science and Technology
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
22342144 72 Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI PanThera Biopharma, LLC
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19635666 119 Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI Incyte Corporation
19095454 63 Current perspective of TACE inhibitors: a review.EBI The M. S. University of Baroda
17981034 51 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.EBI Johnson & Johnson Pharmaceutical Research and Development LLC
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson & Johnson Pharmaceutical Research & Development
17980583 46 Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).EBI Johnson & Johnson Pharmaceutical Research and Development LLC
18086526 85 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.EBI Johnson & Johnson Pharmaceutical Research and Development LLC
18257543 16 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI The Hebrew University of Jerusalem
18251495 69 Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
18029173 316 Synthesis and evaluation of novel heterocyclic MMP inhibitors.EBI North Dakota State University
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
15713379 40 N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI Universit£ degli Studi di Pisa
15139754 17 Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase.EBI De Novo Pharmaceuticals Ltd.
15214773 76 Fragment-based drug discovery.EBI Sunesis Pharmaceuticals Inc
15139760 110 Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.EBI The Hebrew University of Jerusalem
12930146 170 Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.EBI Institut de Recherches Servier
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
12773041 119 Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11831904 172 New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.EBI Nippon Organon K.K.
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
11472202 143 Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI TBA
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
10649971 180 Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI Parke-Davis Pharmaceutical Research
10882358 62 Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.EBI F. Hoffmann-La Roche Inc
10579818 162 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
9888835 42 Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI Procter and Gamble Pharmaceuticals
9733482 31 Discovery of potent, achiral matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
2153207 31 Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.EBI University of Kentucky
15177439 96 Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc
12824028 75 Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.EBI Pfizer Inc
11327577 86 Heterocycle-based MMP inhibitors with P2' substituents.EBI Procter and Gamble Pharmaceuticals
11677139 92 The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.EBI Wyeth-Ayerst Research
11591510 57 alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.EBI Pfizer Inc
11206468 24 Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.EBI Wyeth-Ayerst Research
11206467 44 The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.EBI Wyeth-Ayerst Research
11514167 88 The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.EBI Wyeth-Ayerst Research
11378378 34 Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.EBI Celltech-Chiroscience Ltd
11133099 43 Synthesis and activity of selective MMP inhibitors with an aryl backbone.EBI Pharmacia
10340614 20 Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.EBI DuPont Pharmaceuticals Company
10450979 4 Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.EBI University of Cambridge
10397503 40 Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.EBI Universit£ de Montr£al
9873598 39 The synthesis and biological activity of a novel series of diazepine MMP inhibitors.EBI Wyeth-Ayerst Research
22386984 67 In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI Colosseum Combinatorial Chemistry Centre for Technology (C4T SCarl)
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc
22153941 140 Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI AstraZeneca
22018790 9 Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.EBI Scripps Florida
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
22082667 67 Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI Microbiotix Inc
22088955 33 Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.EBI Universit£ di Napoli Federico II Via D. Montesano 49
21925881 60 Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.EBI Johnson & Johnson Pharmaceutical Research & Development
21548582 57 Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.EBI University of Illinois at Chicago
21866961 28 Selective water-soluble gelatinase inhibitor prodrugs.EBI University of Notre Dame
20726512 282 Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI Pfizer Inc
21514700 56 Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI Universit£ di Pisa
21536437 219 Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI AstraZeneca
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21507637 102 MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI Pfizer Inc
21493063 67 MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI Pfizer Inc
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21417219 179 Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.EBI Central Pharmaceutical Research Institute
21300546 129 The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI AstraZeneca
24900296 38 Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI TBA
20965620 50 Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).EBI ProtEra s.r.l.
21078557 34 Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.EBI Yonsei University
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20529685 70 MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI Pfizer Inc
20529684 112 Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI Pfizer Inc
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
19767207 17 Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.EBI Central Pharmaceutical Research Institute
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19775099 184 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI Universit£ di Pisa
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
19606871 124 N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI Universit£ di Pisa
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering-Plough Research Institute
 97 Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI TBA
 1 Asymmetric synthesis of a conformationally constrained N-phosphonoalkyl dipeptideEBI TBA
 30 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimicsEBI TBA
 30 Orally active inhibitors of stromelysin-1 (MMP-3)EBI TBA
 60 Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptidesEBI TBA
 49 Phosphinic acid inhibitors of matrix metalloproteinasesEBI TBA
 44 Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistryEBI TBA
 15 Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the N-carboxyalkylamine and glutaramide carboxylate seriesEBI TBA
 12 Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate seriesEBI TBA
 36 Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostereEBI TBA
 18 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'EBI TBA
 47 Hydroxamate inhibitors of human gelatinase B (92 kDa)EBI TBA
 39 Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modificationsEBI TBA
 19 Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitorsEBI TBA
 15 Synthesis of thiophenol derivatives as inhibitors of human collagenaseEBI TBA
 11 Inhibitors of human collagenase: dipeptide mimetics with lactam and azalactam moieties at the P2′/P3′ positionEBI TBA
 66 Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalaninesEBI TBA
 5 Inhibition of metalloproteinase by futoenone derivativesEBI TBA
 40 Novel indolactam-based inhibitors of matrix metalloproteinasesEBI TBA
 14 Aminophosphonic acid containing inhibitors of human collagenase: modification of the P1 residueEBI TBA
 2 Synthesis and biological evaluation of a library containing potentially 1600 amides / esters. A strategy for rapid compound generation and screening.EBI TBA
 60 Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivativesEBI TBA
 76 Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivativesEBI TBA
 26 Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acidsEBI TBA
19457660 90 Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI Incyte Corporation
19410464 71 Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI Wyeth Research
19329309 49 Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.EBI Wyeth Research
19261472 16 Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.EBI University of California
19053764 101 Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI Instituto Superior Técnico
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Inc
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18782669 90 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI Université de Reims-Champagne-Ardenne
18691892 52 Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat.EBI Merck Research Laboratories
17719700 39 Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI Università G. d'Annunzio
17623656 34 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI Pfizer Inc
18083558 112 beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.EBI Johnson & Johnson Pharmaceutical Research and Development LLC
18068976 132 Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI Incyte Corporation
18036818 157 Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI Incyte Corporation
18029177 57 A novel series of highly selective inhibitors of MMP-3.EBI Pfizer Inc
17591762 102 Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI Pfizer Inc
17512742 32 Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI Université de Reims-Champagne-Ardenne
17368021 55 Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17256836 84 Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI Incyte Corporation
17188863 107 Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17088065 106 alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI Università "G. d'Annunzio"
17064892 123 Identification of potent and selective TACE inhibitors via the S1 pocket.EBI Wyeth Research
17027261 153 Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16723229 108 Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI Wyeth Research
16632358 68 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.EBI Johnson & Johnson Pharmaceutical Research and Development LLC
16516469 39 A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.EBI Novartis Institutes for BioMedical Research
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16426848 80 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.EBI Wyeth Research
16420030 38 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI Chinese Academy of Sciences
16392792 29 Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI Aventis Pharma Deutschland GmbH
16289878 35 Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16220975 40 Receptor flexibility in de novo ligand design and docking.EBI De Novo Pharmaceuticals
16153831 87 Synthesis and SAR of highly selective MMP-13 inhibitors.EBI Wyeth Research
16084720 83 Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.EBI Wyeth Research
16005220 52 Identification of potent and selective MMP-13 inhibitors.EBI Wyeth Research
16002291 24 Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.EBI Pfizer Inc
15953722 56 Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI Pfizer Inc
15911259 49 Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.EBI Pfizer Inc
15908214 95 Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15837315 13 A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI Università degli Studi di Pisa
15780611 74 Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.EBI Pfizer Inc
15745814 75 Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.EBI Wyeth Research
15686921 55 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI Pharmaceutical Research Institute
15566296 142 Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.EBI Wyeth Research
15357971 228 Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15341955 52 Synthesis and evaluation of novel oxazoline MMP inhibitors.EBI North Dakota State University
15324896 71 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI Pfizer Inc
15261259 48 Benzodiazepine inhibitors of the MMPs and TACE. Part 2.EBI Wyeth Research
15055993 30 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.EBI Hokkaido Collaboration Center N-21
15006405 20 Synthesis and biological activity of selective azasugar-based TACE inhibitors.EBI Organon K.K.
14711305 26 Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI University of Athens
14684295 109 Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI Chinese Academy of Sciences
14643313 132 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14643312 39 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12951101 79 Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.EBI Pfizer Inc
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Inc
12873518 81 Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.EBI Wyeth Research
12873505 20 Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12873504 36 Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12824039 56 Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.EBI CombiChem Inc.
12798337 6 Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI Indiana University School of Medicine
12781190 113 Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12781187 15 Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Organon K.K.
12729664 14 Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.EBI Université de Reims-Champagne-Ardenne
12723945 167 Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12668018 138 Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.EBI Wyeth-Ayerst Research
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Co.
12270165 80 Benzodiazepine inhibitors of the MMPs and TACE.EBI Wyeth Research
11992783 78 Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Pfizer Inc
11934588 69 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.EBI Wyeth-Ayerst Research
11934587 19 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.EBI Wyeth-Ayerst Research
11844676 48 Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.EBI Organon K.K.
11831905 33 New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.EBI Organon K.K.
11814800 14 Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin.EBI Organon K.K.
11754593 148 Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI Abbott Laboratories
11738583 45 Potent P1' biphenylmethyl substituted aggrecanase inhibitors.EBI Bristol-Myers Squibb Pharma Company
11708926 84 Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI GlaxoSmithKline
11677124 67 Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Abbott Laboratories
11591509 46 alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.EBI Pfizer Inc
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11585439 44 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.EBI DuPont Pharmaceuticals Company
11563922 147 Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI Universität Bielefeld
11551755 18 Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI British Biotech Pharmaceuticals Limited
11543676 45 Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.EBI Université de Montréal
11543675 104 N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.EBI Université de Montréal
11514157 48 N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.EBI GlaxoSmithKline
11454461 111 The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI Procter and Gamble Pharmaceuticals
11428927 117 A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.EBI The Royal Danish School of Pharmacy
11412980 48 Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI Abbott Laboratories
11412979 67 Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.EBI Abbott Laboratories
11354379 37 Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.EBI Pfizer Inc
11327602 58 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI Roche Research Center
11297453 173 Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.EBI Procter and Gamble Pharmaceuticals
11229774 40 Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI Pfizer Inc
11229773 73 Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI Pfizer Inc
11212095 65 General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.EBI Institut de Recherches Servier
11150165 228 Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI Procter and Gamble Pharmaceuticals
10937713 186 Solid-phase synthesis of an arylsulfone hydroxamate library.EBI Rhone-Poulenc Rorer
10882354 19 Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.EBI Pfizer Inc
10794702 340 Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.EBI Università degli Studi
10669564 189 Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
10639284 119 Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI University of Florida
10579851 151 New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.EBI AstraZeneca
10560745 46 Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.EBI SmithKline Beecham Pharmaceuticals Ltd
10522712 109 The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.EBI British Biotech Pharmaceuticals Limited
10411481 144 Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI CEA
10406637 20 Synthesis and identification of conformationally constrained selective MMP inhibitors.EBI Searle Discovery Research
10360755 17 P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.EBI DuPont Pharmaceuticals Company
10230616 30 Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.EBI Searle Discovery Research
10229623 82 Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.EBI Pharmacia and Upjohn, Inc.
10212120 34 Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.EBI Affymax Research Institute
10052961 24 Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.EBI Rhône-Poulenc Rorer
10021927 80 Design and synthesis of thiol containing inhibitors of matrix metalloproteinases.EBI Novartis Biomedical Research Institute
10021913 42 Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.EBI Pfizer Inc
9873712 109 Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI Abbott Laboratories
9873491 56 The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI Abbott Laboratories
9873489 28 Design and synthesis of conformationally-constrained MMP inhibitors.EBI Procter and Gamble Pharmaceuticals
9873367 39 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.EBI Abbott Laboratories
9871728 27 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.EBI Wyeth-Ayerst Research
9871727 58 Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.EBI Affymax Research Institute
9871623 48 Selective inhibition of low affinity IgE receptor (CD23) processing.EBI SmithKline Beecham Pharmaceuticals Ltd
9871622 36 Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing.EBI SmithKline Beecham Pharmaceuticals Ltd
9871551 48 Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.EBI DuPont Pharmaceuticals Company
9632351 36 Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.EBI Affymax Research Institute
9599226 25 Macrocyclic amino carboxylates as selective MMP-8 inhibitors.EBI DuPont Pharmaceuticals Company
9599225 9 Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.EBI DuPont Pharmaceuticals Company
9548812 67 Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI Kanebo Ltd.
9484512 130 Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI Shionogi & Co., Ltd
9191969 31 Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.EBI Institut de Recherche Servier
8289190 31 Synthesis of novel N-phosphonoalkyl dipeptide inhibitors of human collagenase.EBI SmithKline Beecham Pharmaceuticals Ltd
8277511 57 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.EBI Merck Research Laboratories
8258825 31 Synthesis of novel modified dipeptide inhibitors of human collagenase: beta-mercapto carboxylic acid derivatives.EBI SmithKline Beecham Pharmaceuticals Ltd
8126708 113 Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.EBI Glaxo Inc. Research Institute
23688254 31 Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.EBI ETH Zurich
7629797 73 Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.EBI Sterling Winthrop Pharmaceuticals Research Division
12014967 25 Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.EBI Preclinical Research Novartis Pharma AG
29727184 56 Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.EBI Universit£ di Pisa
28818461 67 Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.EBI Nestl� Skin Health R&D
30249495 241 Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.EBI Graz University of Technology
30034605 15 In Search of Selectivity in Inhibition of ADAM10.EBI University of Notre Dame
29028530 48 A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line.EBI Jadavpur University
28850227 85 Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.EBI St. John's University
28558971 38 Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.EBI Merck & Co.
28653849 67 Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.EBI Department of Chemistry, Scripps Florida , 130 Scripps Way, Jupiter, Florida 33458, United States.
22299577 12 Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.BDB UniversitÓ di Firenze
21524149 13 Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB Suven Life Sciences Ltd
16206837 9 Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.BDB University of Karachi
9463476 21 DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.BDB Suntory Institute for Bioorganic Research
8632342 110 Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.BDB Eli Lilly and Company
7680751 48 Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.BDB National Institute of Neurological Disorders and Stroke
18355729 12 Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin.BDB University of Dundee
19695884 156 Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.BDB Vernalis (R&D) Ltd
17034127 45 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.BDB University of Newcastle upon Tyne
19345579 14 Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.BDB Wyeth Research
19267461 53 Novel tricyclic inhibitors of IkappaB kinase.BDB Bristol-Myers Squibb Co.